ExpreS2ion Biotech Holding AB (publ) (STO: EXPRS2)

Sweden flag Sweden · Delayed Price · Currency is SEK
24.85
-0.30 (-1.19%)
Nov 12, 2024, 5:29 PM CET
-39.09%
Market Cap 52.19M
Revenue (ttm) 8.10M
Net Income (ttm) -45.37M
Shares Out 2.10M
EPS (ttm) -35.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 52,605
Open 25.20
Previous Close 25.15
Day's Range 23.35 - 27.95
52-Week Range 23.35 - 198.26
Beta 1.61
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2024

About EXPRS2

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine for breast cancer that targets the human epidermal growth factor receptor 2 receptor. It is also developing ES2B-I002, a cytomegalovirus vaccine candidate to treat infectious diseases. In addition, the company out licenses its ExpreS2 platform to research institutes and pharmaceutical compa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 21
Stock Exchange Nasdaq Stockholm
Ticker Symbol EXPRS2
Full Company Profile

Financial Performance

In 2023, EXPRS2's revenue was 8.80 million, an increase of 43.07% compared to the previous year's 6.15 million. Losses were -91.40 million, -22.94% less than in 2022.

Financial Statements

News

There is no news available yet.